Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy

BACKGROUND: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years. METHODS: One hundred seventy-two consecutive eyes of 163 prospective treatment-naïve patients with PCV w...

Descripción completa

Detalles Bibliográficos
Autor principal: Hikichi, Taiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393615/
https://www.ncbi.nlm.nih.gov/pubmed/25881324
http://dx.doi.org/10.1186/s12886-015-0026-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393615/
https://www.ncbi.nlm.nih.gov/pubmed/25881324
http://dx.doi.org/10.1186/s12886-015-0026-y

Ejemplares similares